Lung Cancer​​

We are advancing next-generation therapies for lung cancer, including non-small cell lung cancer (NSCLC) and other difficult-to-treat subtypes. By leveraging translational medicine and our expertise in immune-cell biology, we develop therapies designed to enhance immune-cell fitness and resilience, enabling more durable responses in patients with advanced lung cancer.

Viral Infections​​​

We are advancing next-generation immunotherapies for viral infections, including COVID 19, SARS, Influenza (H5N1) and RSV, by addressing the underlying immune dysfunction that allows viral persistence. Through translational research and deep understanding of T cell exhaustion in viral infections, we aim to reprogram dysfunctional immune cells and restore durable antiviral immunity—offering the potential for functional cure in patients with lung infections.​

Idiopathic Pulmonary Fibrosis (IPF)​​

Oncofibro is dedicated to addressing the unmet needs in idiopathic pulmonary fibrosis—a progressive, life-limiting lung disease with limited treatment options. Our research focuses on developing precision-targeted therapies that aim to slow or halt fibrotic progression, preserving lung function and improving patient outcomes.​

Broadening the reach ​

While our primary focus remains on lung cancer, viral infections, and lung fibrosis, the platform technology’s unique ability to restore immune function and enhance cell survival/proliferation positions it for broader therapeutic applications:​ ​

• Other Solid Tumors – Including liver cancer, colorectal, pancreatic, ovarian, glioblastoma, sarcoma, bile duct, esophageal, laryngeal, mesothelioma, peritoneal, and other high-mortality cancers where immune exhaustion severely limits current treatments.
• Chronic Viral Infections Such as Hepatitis B infection and other conditions where T-cell anergy and exhaustion hinder effective viral clearance.
• Hematopoietic Stem Cell (HSC) Transplantation Our platform also supports HSC applications, with potential use across cord blood, G-CSF–mobilized peripheral blood, and bone marrow sources. Transient ex vivo exposure to the fusion protein enhances HSC survival by upregulating Akt–Bcl-2 pro-survival pathways and reducing GranzymeB-mediated stress injury during mobilization and conditioning. This results in more resilient HSCs, enabling faster engraftment and improved immune reconstitution following HSCT.

hematopoietic stem cell (HSC) applications are currently in preclinical development. To advance this program into a first-in-human Phase I study, we are actively seeking licensing partners, philanthropic funding, and grant support.